Tom 14, Nr 4 (2023)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2024-01-04
Wyświetlenia strony
266
Wyświetlenia/pobrania artykułu
15
Rola nutraceutyków w leczeniu dyslipidemii
Forum Zaburzeń Metabolicznych 2023;14(4):160-169.
Streszczenie
Rosnąca liczba pacjentów z dyslipidemią i związanych z nią powikłań sercowo-naczyniowych jest istotnym problemem klinicznym. Poszukuje się nowych rozwiązań terapeutycznych, które pomogą w optymalizacji profilu lipidowego pacjentów. Coraz większą uwagę przywiązuje się do stosowania bioaktywnych substancji — nutraceutyków. Liczne badania kliniczne potwierdzają skuteczność działania hipolipemizującego wybranych nutraceutyków w kontekście wspomagania farmakoterapii. Ze względu na profil działania wyróżnia się: 1) inhibitory jelitowego wchłaniania cholesterolu, 2) inhibitory wątrobowej syntezy cholesterolu, 3) składniki promujące wydalanie LDL-cholesterolu oraz 4) preparaty o mieszanym mechanizmie działania. Biorąc pod uwagę siłę dowodu naukowego, w pracy omówiono rolę i znaczenie wybranych nutraceutyków: czerwonego ryżu drożdżowego, steroli roślinnych, glukomannanu, czosnku, pantetyny, berberyny, zielonej herbaty, kwasów tłuszczowych z rodziny n-3 oraz kurkuminy.
Słowa kluczowe: sterole roślinneberberynamonakolina Kkwasy tłuszczowe n-3
Referencje
- Penson PE, Banach M. Nutraceuticals for the control of dyslipidaemias in clinical practice. Nutrients. 2021; 13(9).
- Derosa G, Colletti A, Maffioli P, et al. Lipid-lowering nutraceuticals update on scientific evidence. J Cardiovasc Med (Hagerstown). 2020; 21(11): 845–859.
- Cheung B, Sikand G, Dineen EH, et al. Lipid-Lowering nutraceuticals for an integrative approach to dyslipidemia. J Clin Med. 2023; 12(10).
- Cicero AFG, Fogacci F, Stoian AP, et al. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels? Curr Atheroscler Rep. 2021; 23(10): 57.
- Banach M, Burchardt P, Chlebus K. Wytyczne PTL/KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. 2021: 137–138 (44–45).
- Gerards MC, Terlou RJ, Yu H, et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015; 240(2): 415–423.
- Yuan R, Yuan Y, Wang L, et al. Red yeast rice preparations reduce mortality, major cardiovascular adverse events, and risk factors for metabolic syndrome: a systematic review and meta-analysis. Front Pharmacol. 2022; 13: 744928.
- Ye P, Lu ZL, Du Bm, et al. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J Am Geriatr Soc. 2007; 55(7): 1015–1022.
- Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of monacolins in red yeast rice. EFSA J. 2018; 16(8): e05368.
- Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014; 112(2): 214–219.
- Ying J, Zhang Y, Yu K. Phytosterol compositions of enriched products influence their cholesterol-lowering efficacy: a meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2019; 73(12): 1579–1593.
- Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008; 88(4): 1167–1175.
- Ho HV, Jovanovski E, Zurbau A, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. Am J Clin Nutr. 2017; 105(5): 1239–1247.
- Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013; 71(5): 282–299.
- Evans M, Rumberger JA, Azumano I, et al. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014; 10: 89–100.
- Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 69–81.
- Derosa G, D'Angelo A, Bonaventura A, et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013; 13(4): 475–482.
- Onakpoya I, Spencer E, Heneghan C, et al. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014; 24(8): 823–836.
- Fatahi S, Sohouli MH, da Silva Magalhães EI, et al. Comparing the effects of docosahexaenoic and eicosapentaenoic acids on cardiovascular risk factors: Pairwise and network meta-analyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2023; 33(1): 11–21.
- Eslick GD, Howe PRC, Smith C, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009; 136(1): 4–16.
- Zhang HJ, Gao X, Guo XF, et al. Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: a systematic review and meta-analysis of data from 33 randomized controlled trials. Clin Nutr. 2021; 40(7): 4538–4550.
- Leslie MA, Cohen DJA, Liddle DM, et al. A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis. 2015; 14: 53.
- Ursoniu S, Sahebkar A, Serban MC, et al. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2017; 75(5): 361–373.
- Pan An, Yu D, Demark-Wahnefried W, et al. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 2009; 90(2): 288–297.
- Khalili L, Nammi S. The effects of curcumin supplementation on metabolic biomarkers and body mass index in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2022; 28(23): 1911–1925.
- Yang YS, Su YF, Yang HW, et al. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014; 28(12): 1770–1777.
- Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. 2014; 33(3): 406–414.
